Kairos Pharma Reports Promising Phase 2 Results for ENV105 Prostate Cancer Treatment
TL;DR
Kairos Pharma's ENV105 combination therapy offers investors a competitive edge with median progression-free survival exceeding 13 months versus standard 3.7 months in prostate cancer.
ENV105 targets CD105 protein to reverse drug resistance, combining with apalutamide to achieve PSA declines in 7 of 9 patients with no dose-limiting toxicities observed.
This breakthrough therapy extends survival for metastatic prostate cancer patients, reducing treatment resistance and improving quality of life for those facing limited options.
Kairos Pharma's antibody therapy defies cancer drug resistance, showing remarkable 13+ month survival in patients who previously had only 3.7 months expected.
Found this article helpful?
Share it with your network and spread the knowledge!
Kairos Pharma Ltd. (NYSE American: KAPA) announced positive interim efficacy data from its ongoing Phase 2 trial of ENV105 (carotuximab) in metastatic castration-resistant prostate cancer. The clinical-stage biopharmaceutical company reported that among eight evaluable patients, the ENV105 and apalutamide combination achieved median progression-free survival of more than 13 months, significantly exceeding the trial's target of a 45% improvement compared to the standard 3.7 months for second- or third-line hormone therapy.
The interim data revealed that five patients remain on treatment, with seven of nine patients showing declines in prostate-specific antigen levels, indicating positive treatment response. The treatment combination demonstrated favorable safety profiles, being well tolerated with no dose-limiting toxicities observed during the study period. These results are particularly significant given that metastatic castration-resistant prostate cancer represents an advanced stage of the disease where treatment options are limited and often ineffective.
ENV105 is an antibody that targets CD105, a protein identified as a key driver of resistance to various cancer treatments. According to company information available at https://ibn.fm/BSLuY, elevation of CD105 in response to standard therapy results in resistance and disease relapse. The drug candidate aims to reverse drug resistance by targeting CD105 and restore the effectiveness of standard therapies across multiple cancer types.
The positive interim results have important implications for prostate cancer treatment, particularly for patients who have developed resistance to existing therapies. Prostate cancer remains one of the most common cancers among men worldwide, and the castration-resistant form represents a significant clinical challenge with limited effective treatment options. The extended progression-free survival observed in this trial suggests ENV105 could potentially address this unmet medical need.
Kairos Pharma is currently conducting additional clinical trials for ENV105, including a Phase 1 trial for lung cancer. The company's approach utilizing structural biology to overcome drug resistance and immune suppression in cancer represents an innovative strategy in oncology drug development. Further details about the company's developments can be found at https://ibn.fm/KAPA.
The promising interim data position ENV105 as a potential breakthrough therapy for treatment-resistant prostate cancer patients. If these results are sustained in larger patient populations and subsequent clinical trials, ENV105 could become an important addition to the limited arsenal of treatments available for advanced prostate cancer patients who have exhausted standard treatment options.
Curated from InvestorBrandNetwork (IBN)
